This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jeremy Sugarman, MD, MPH, MA; Emily G. Reisner, PhD; Joanne Kurtzberg, MD
Duke University Medical Center Durham, NC

JAMA. 1996;275(12):910.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Howe mistakenly suggests that we have argued for evaluating the safety and efficacy of UCB in populations that would not have access to this technology for "financial or other reasons." Our argument for establishing publicly funded UCB banks that recruit donations from people of "all races, income levels, and ethnic groups" assumes that provisions are made for making UCB available to all who need it. Although Howe misinterprets our arguments, we agree that there should be a mechanism to provide donor families with coverage toward a transplant in the event such therapy is needed.

Howe's claim regarding the likelihood that banked UCB will be limited to an affluent minority is really an incompletely tested empirical claim that embraces important cautions for those developing procedures for UCB banking. Nevertheless, it is encouraging that in contrast to the trends in transplant management cited by Howe, early experience suggests that . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?